<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00595647</url>
  </required_header>
  <id_info>
    <org_study_id>BASKET-SAVAGE EKBB# 278/07</org_study_id>
    <secondary_id>SNF 3200B0_120029</secondary_id>
    <secondary_id>EKBB 278/07</secondary_id>
    <nct_id>NCT00595647</nct_id>
  </id_info>
  <brief_title>Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions</brief_title>
  <acronym>BASKET-SAVAGE</acronym>
  <official_title>BAsel Stent Kosten Effektivitäts Trial - SAphenous Venous Graft Angioplasty Using Glycoprotein IIb/IIIa Receptor Inhibitors and Drug-Eluting Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicenter controlled randomized trial to compare the safety and efficacy of
      drug eluting vs. bare metal stents in percutaneous coronary interventions of saphenous vein
      grafts. Hypothesis: Survival and outcome will be significantly better in patients receiving
      DES than in patients receiving BMS regarding both short-term and long-term outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Question: What is the effect of the paclitaxel eluting TAXUS® Liberté® stent
      compared with the bare-metal Liberté® stent (both Boston Scientific Corporation, Natick, MA)
      in saphenous vein graft (SVG) percutaneous coronary interventions (PCI) when used in
      conjunction with a glycoprotein IIb/IIIa inhibitor, e.g., abciximab (ReoPro®, Eli Lilly &amp;
      Co., Indianapolis, IN), and a distal filter system? Design: Prospective, multicenter,
      controlled randomized trial. Subjects: Inclusion criteria: Patients undergoing SVG PCI with a
      target vessel reference diameter ≤ 5.5 mm (visual estimate); documented silent ischemia,
      stable angina pectoris Canadian Cardiovascular Society (CCS) class I to IV, or acute coronary
      syndrome. Exclusion criteria: Previous stent implantation anywhere in the target SVG;
      concomitant native vessel PCI; SVG age &lt;6 months; arterial grafts; oral anticoagulation;
      platelet count &lt;100x109/L or &gt;700x109/L; any major non-cardiac condition with a life
      expectancy &lt;12 months; known allergies against the components tested; white blood cell count
      &lt;3000 cell/mm3; enrolled in other study; no consent; patients unlikely to comply to the study
      treatment and the follow-up visits. Recruitment: Consecutive sample of all patients who
      qualify Variables: Predictor: Randomization will be single-blinded 1:1 to the TAXUS® Liberté®
      vs. the Liberté® stent (both Boston Scientific Corporation, Natick, MA). In all patients, a
      distal filter system will be used during PCI. The use of a glycoprotein IIb/IIIa inhibitor,
      e.g., abciximab (ReoPro®, Eli Lilly &amp; Co., Indianapolis, IN), will be strongly recommended
      (bolus prior to PCI and 12 h infusion post PCI). Outcome: Primary: MACE after 12 months. MACE
      will be defined as the composite of cardiac death (all deaths not clearly non-cardiac),
      non-fatal myocardial infarction, and TVR. Secondary: Non-fatal myocardial infarction and
      cardiac death at 30 days and 6, 12, 36, and 60 months; MACE at 30 days and 6, 36, and 60
      months; quality of life; individual components of the primary endpoint; non-cardiac death;
      major bleeding, defined as need for surgery, need for blood transfusions, and cerebral
      hemorrhage during antiplatelet therapy; minor bleeding, defined as a drop in hematocrit of &gt;2
      mg/dL.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE (composite of cardiac death, i.e., all deaths not clearly non-cardiac, non-fatal myocardial infarction, and TVR</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-fatal MI and cardiac death; MACE; QoL; individual components of the primary endpoint; non-cardiac death; major bleeding; minor bleeding</measure>
    <time_frame>30 days and 6, 12, 36, and 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Percutaneous coronary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting stent</intervention_name>
    <description>Implantation of stent</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TAXUS Liberté</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bare metal stent</intervention_name>
    <description>Implantation of stent</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Liberté</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing SVG PCI with a target vessel reference diameter ≤ 5.5 mm (visual
             estimate)

          -  Documented silent ischemia, stable angina pectoris Canadian Cardiovascular Society
             (CCS) class I to IV, or acute coronary syndrome

        Exclusion Criteria:

          -  Previous stent implantation anywhere in the target SVG

          -  Concomitant native vessel PCI

          -  SVG age &lt;6 months

          -  Arterial grafts

          -  Oral anticoagulation

          -  Platelet count &lt;100x109/L or &gt;700x109/L, white blood cell count &lt;3000 cells/mm3

          -  Any major non-cardiac condition with a life expectancy &lt;12 months

          -  Planned elective surgery in the next 12 months

          -  Known allergies against the components tested

          -  Enrolled in other study

          -  No consent

          -  Patients unlikely to comply to the study treatment and the follow-up visits

          -  Age &lt;18 years

          -  Known pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Pfisterer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raban Jeger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sven Möbius-Winkler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig/Heart Center, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig/Heart Center</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triemli Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <last_update_submitted>April 19, 2015</last_update_submitted>
  <last_update_submitted_qc>April 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Raban Jeger</investigator_full_name>
    <investigator_title>PD Dr. med. / MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

